PMC Ciliopathies Panel

Up to 190 genes Turn around Time: 10 business days
Order a Kit:

Testing Kit Request Form

New Provider:

Please fill out the form:
Provider Registration Form

Contact:

info@pmcdx.com

Test Description

PMC Ciliopathies Panel analyzes the genes involved in ciliopathy syndromes. Due to overlapping clinical features of hereditary susceptibility conditions| utilizing a comprehensive panel test enables a thorough evaluation of potential genes for individuals with similar clinical manifestations. Some genes in this panel may also be linked to conditions that are not related to the primary reason for testing.

  • Associated Conditions
    • Alström syndrome
    • Autosomal dominant polycystic kidney disease (ADPKD)
    • Autosomal recessive polycystic kidney disease (ARPKD)
    • Bardet-Biedl syndrome
    • Cystic fibrosis
    • DREAM-PL syndrome (dysmorphic facies, renal agenesis, ambiguous genitalia, microcephaly, polydactyly, and lissencephaly)
    • Ellis-van Creveld syndrome
  • Methodology

    Targeted Exome/ Slice Exome (Next Generation Sequencing including Copy Number Variation)

  • Assay Information
    • PIBF1: Sequencing analysis for exons 16 includes only cds +/- 10 bp.
    • CEP290: Analysis includes the intronic variant NM_025114.3:c.2991+1655A >G.
    • NOTCH2: Deletion/duplication and sequencing analysis is not offered for exons 1-4.
    • RPGR: To detect X-linked retinitis pigmentosa sequence variants in exon 15 of NM_001034853.2| RPGR (ORF15) must also be analyzed.
    • LRRCC1: Deletion/duplication analysis is not offered for exon 3. Sequencing analysis for exons 3 includes only cds +/- 10 bp.
    • ARMC4: Deletion/duplication and sequencing analysis is not offered for exon 9.
    • CRB2: Deletion/duplication analysis is not offered for exons 5-6.
  • Limitations

    All sequencing technologies have limitations. A negative result from this analysis does not rule out a possible genetic diagnosis as some variants may not be detected by this test. This test is not designed to detect low level mosaicism, structural rearrangements, indels >40bp, deep intronic variants of unknown clinical significance, or large cytogenetic CNVs. Certain inherent qualities of the human genome, for example repetitive regions/homopolymers, GC rich, pseudogenes, and rare polymorphisms, pose significant technical challenges such as sequence misalignment that may potentially impact the accuracy of the results. False negative results may also occur in the setting of allogeneic bone marrow, stem cell transplantation, active or chronic hematologic conditions, recent blood transfusions, suboptimal DNA quality or PCR trace contamination. Other potential sources of error include sample mix-ups and clerical issues.

  • References
    • 1. Richards S et al. Genetics in medicine. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. 2015 May;17(5):405-24 (PMID: 25741868)
    • 2. GnomAD (gnomAD)
    • 3. CSPEC (ClinGen variant classification rules registry) Criteria Specification Registry
    • 4. Normal copy number variation in healthy individuals database of genomic variants: http://dgv.tcag.ca/dgv/app/home
  • Tagged Genes

    Primary panel:

    190 genes selected